Lead Product(s): ARQ 531
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co. Inc.
Deal Size: $2,700.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition January 17, 2020
ArQule became a wholly owned subsidiary of Merck upon completion of the acquisition.